Equecabtagene Autoleucel
福可苏
A Chinese-developed BCMA CAR-T cell therapy for multiple myeloma.
At a glance
China price
Verified pricing is not currently available.
NRDL (national insurance)
Not in NRDL — self-pay.
Regulatory status
NMPA approved (2023)
What this meansSupported by a credible secondary source but not yet independently confirmed against a primary source.
SourceNo independent source on file.
NotesApproval status from public regulatory reporting.
What it treats
Relapsed/refractory multiple myeloma.
How it is accessed in China
- CAR-T
Related treatments
Sources & verification
No independent source is currently on file. We have not independently verified this information.
Reader discussion
Public comments about Equecabtagene Autoleucel. Discussion is not medical advice, and a comment is not an endorsement or a verified fact. Open the full forum.